Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure Academic Article uri icon

Overview

MeSH Major

  • Androgen Antagonists
  • Antineoplastic Agents, Hormonal
  • Biomarkers, Tumor
  • Prostate-Specific Antigen
  • Prostatic Neoplasms

abstract

  • A PSA nadir of more than 0.2 ng/mL after 8 months of AST given for postoperative or postradiation PSA failure is significantly associated with PCSM and is clinically significant because it accounted for 75% of the cancer deaths observed in this study.

publication date

  • September 20, 2005

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2005.20.966

PubMed ID

  • 16170163

Additional Document Info

start page

  • 6556

end page

  • 60

volume

  • 23

number

  • 27